Qijun Lv

Qijun Lv

Auto-generated profile, based on publicly available information

Qijun Lv

Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YLYuhang Liu
Yuhang Liu
HYHaoyu Yun
Haoyu Yun
WZWei Zhang
Wei Zhang
HZHan Zou
Han Zou
NCNuojun Chen
Nuojun Chen
QLQijun Lv
Qijun Lv
Background: While robotic total gastrectomy (RTG) has gained traction in minimally invasive gastric cancer surgery, high-level evidence comparing its efficacy with laparoscopic total gastrectomy (LTG) remains limited. This systematic review and meta-analysis aimed to comprehensively evaluate the comparative efficacy and safety of RTG versus LTG in gastric cancer patients, thereby informing evidence-based surgical decision-making. Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases from inception until November 2024 for comparative studies of RTG and LTG. Perioperative outcomes (intraoperative blood loss, severe complications [Clavien–Dindo grade ≥3], abdominal infection rates, postoperative hospitalization) and oncologic parameters (retrieved lymph nodes, 3-year overall survival [OS], disease-free survival [DFS]) were analyzed. Risk ratios and weighted mean differences (WMD) with 95% confidence intervals were calculated. Protocol registered with PROSPERO. Results: The results revealed that RTG significantly reduced severe complications (CD ≥3), abdominal infection, intraoperative blood loss, and postoperative hospital stay compared to LTG. Additionally, RTG led to an increased number of retrieved lymph nodes. However, no significant differences were observed in 3-year OS and DFS between RTG and LTG, consistent with findings from other types of gastrectomy. The subgroup analysis demonstrated that the use of linear staplers was more effective in reducing severe complications and postoperative hospital stay. Conclusion: RTG confers superior perioperative safety profiles compared to LTG while maintaining equivalent oncologic outcomes. The technical advantages of robotic platforms – particularly enhanced instrument maneuverability in narrow spaces – may explain reduced intraoperative trauma and complication risks. These findings support RTG as a viable option for centers with robotic expertise, though cost-effectiveness analyses remain warranted.

6 February 2025 in Expert Systems with Applications
Verified
Journal Article
Closed access
Fan ZhangFan Zhang
Fan Zhang
QLQijun Lv
Qijun Lv
BPBinrong Pan
Binrong Pan
YWYun Wang
Yun Wang

11 February 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
WSWen Shao
Wen Shao
YLYuhang Liu
Yuhang Liu
LHLina Huang
Lina Huang
SLSihan Lu
Sihan Lu
YZYixiang Zhai
Yixiang Zhai
QLQijun Lv
Qijun Lv
Background: Colorectal cancer (CRC) is a malignant tumor with a high incidence and mortality rate worldwide. The existing treatment methods have limitations in terms of efficacy or applicable population. Bispecific antibodies (BsAbs) can simultaneously target two different antigens and are expected to overcome tumor immune escape, providing a new strategy for the treatment of CRC. Method: This study systematically retrieved clinical trial registration platforms such as Trialtrove and ClinicalTrials.gov up to July and November 2025, and collected trial data on the treatment of CRC with BsAbs. Descriptive analyses were conducted on key indicators such as the stage distribution, primary endpoints, funding types, global distribution, and target combinations of the trials by establishing clear inclusion and exclusion criteria. Result: A total of 192 clinical trials were included. Since 2018, the number of related trials has significantly increased, and the trial phase has shifted from mainly Phase I in the early stage to a substantial growth in Phase II and Phase III trials after 2023-2024. The primary endpoints of the trial were highly concentrated on safety assessment (such as safety/tolerability, adverse events). The industrial sector is the main funder (68.3%), and the number of trials conducted in China (n=125) ranks first in the world. The target combinations are most commonly PD-1/CTLA-4 and PD-1/VEGF, and studies on novel combinations such as EGFR/cMET are also on the rise. Efficacy data from key trials (e.g., Cadonilimab, Amivantamab) demonstrate encouraging response rates in both locally advanced and metastatic settings, particularly in MSS/pMMR populations. Conclusion: The clinical research and development activities of BsAbs in the field of CRC treatment are becoming increasingly active and mature. Currently, the focus is on establishing a safety profile. Dual-target blocking based on PD-1 and strategies targeting EGFR/cMET are the current main research and development directions. In contrast to resource-intensive CAR-T or payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinct practical and mechanistic benefits. In the future, it is necessary to further optimize the design of BsAbs, explore combination therapies and identify predictive biomarkers to promote its clinical transformation and improve the prognosis of CRC patients.

9 October 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
JCJingjing Chen
Jingjing Chen
WZWei Zhang
Wei Zhang
TWTianyi Wang
Tianyi Wang
YFYu Fu
Yu Fu
YQYunhan Qing
Yunhan Qing
QLQijun Lv
Qijun Lv
In patients with locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma, conversion therapy has shown suboptimal efficacy, typically resulting in stable disease (SD) or progressive disease (PD) leading to low surgical conversion rates and unfavorable prognosis. This study seeks to assess the efficacy and safety of superselective transarterial chemoembolization (SSTACE) in treating this specific patient cohort. This retrospective cohort study analyzed patients diagnosed with locally advanced unresectable gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma at the Affiliated Hospital of North Sichuan Medical College between January 2019 and March 2025. All of them underwent a single session of SSTACE, followed by an assessment of surgical resectability one month later. Patients considered resectable underwent gastrectomy with D2 lymphadenectomy, while those deemed unresectable continued with palliative chemotherapy regimens consistent with their pre-SSTACE systemic protocols. The primary endpoint was R0 resection rate, with secondary endpoints, including the postoperative complication rate, tumor regression rate post-chemoembolization, and pathological complete response (pCR) rate. This retrospective study analyzed 16 patients who underwent SSTACE. Tumor regression was observed in 12 patients, eight of whom met the criteria for partial response. In addition, 12 patients who exhibited regression subsequently achieved R0 resection. Pathological complete response (pCR) was observed in three patients. In terms of safety, all adverse events related to SSTACE in the cohort were manageable. The most common adverse events were nausea (43.8%, 7/16), vomiting (37.5%, 6/16), and abdominal pain (37.5%, 6/16). No instances of hepatic dysfunction were reported. In addition, none of the surgical patients experienced major postoperative complications. SSTACE could potentially offer a novel therapeutic approach for patients with locally advanced unresectable GC or GEJ cancer who have shown limited response to systemic chemotherapy/immunotherapy, characterized by SD or PD. This treatment may increase the likelihood of achieving surgical conversion and R0 resection rates while upholding a favorable safety profile.

13 January 2026 in International Journal of Surgery
Verified
Journal Article
Open access
QLQijun Lv
Qijun Lv
PYPengcheng Ye
Pengcheng Ye
JTJi Tang
Ji Tang
QWQinyuan Wang
Qinyuan Wang
JLJunyi Li
Junyi Li
SWShoujiang Wei
Shoujiang Wei
Background: Single-incision laparoscopic surgery (SILS) is an established minimally invasive option for radical colorectal cancer resection, but its wider adoption is limited by technical challenges.This study introduces an innovative SILS technique with a transabdominal retroperitoneal approach (TRPA) to enhance its feasibility. Objective: This study aimed to evaluate the feasibility and safety of single-incision laparoscopic surgery with transabdominal retroperitoneal approach (SILS-TRPA) for the treatment of patients with sigmoid colon/rectal cancer. Materials and Methods: This prospective IDEAL stage 1 study included 36 patients at the affiliated hospital of North Sichuan Medical College from 12 October 2022 to 31 December 2024. All procedures were performed by the same surgical team. The short-term efficacy and safety of this surgical strategy were preliminarily studied by collecting and analyzing the demographic information, clinical characteristics, surgical outcomes and postoperative recovery indicators of this group of patients. Results: The median age of patients was 70.6 years (IQR 61–77), with a median body mass index of 24.8 kg/m 2 (IQR 21.0–28.2). Twenty-four patients had underlying respiratory conditions of chronic obstructive pulmonary disease (COPD). All patients successfully completed the SILS without conversion to laparotomy. The median total operating time was 118.75 minutes. The mean arterial carbon dioxide pressure during the extraperitoneal phase was significantly lower (32.7 mmHg) compared to the intraperitoneal phase (45.3 mmHg). The median estimated blood loss was 19.20 mL, with no blood transfusions required and no significant operative complications reported. Pathological analysis revealed that 77.78% of patients had advanced disease (stage III), and the average number of harvested lymph nodes was 21.32. Postoperatively, patients experienced a mean time to ambulation of 1.38 days and a mean hospital stay of 6.17 days. Complications occurred in 11patients (30.56%), which were primarily classified as grade I and II according to the Clavien–Dindo classification. Notably, there were no cases of anastomotic leakage or severe complications. Conclusion: The SILS-TRPA for sigmoid colon/upper rectal cancer demonstrates effective oncological management with minimal complications and a favorable recovery profile. The results suggest that this technique is a viable option for patients with sigmoid colon/upper rectal cancer, particularly in those with significant comorbidities.

8 October 2026 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
YLYuhang Liu
Yuhang Liu
HZHan Zou
Han Zou
YZYixiang Zhai
Yixiang Zhai
YXYue Xiong
Yue Xiong
QLQijun Lv
Qijun Lv